What Happened?
Shares of healthcare company Baxter International (NYSE: BAX) fell 13.5% in the morning session after the company reported disappointing third-quarter financial results, which included a miss on revenue and a weak outlook.
While its adjusted earnings of $0.69 per share surpassed analysts' expectations, investors focused on the negatives. The medical device maker's revenue of $2.84 billion fell short of forecasts. Adding to concerns, Baxter issued revenue guidance for its fourth quarter that was well below consensus estimates and also lowered its full-year adjusted earnings guidance, signaling potential challenges ahead. The report also showed that cash generation weakened, with the company's free cash flow margin falling to 4.4% from 8.6% in the same period last year. This combination of a sales miss and a cautious forecast led to a significant sell-off in the shares.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Baxter? Access our full analysis report here.
What Is The Market Telling Us
Baxter’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. Moves this big are rare for Baxter and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 20 days ago when the stock dropped 3% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.
Baxter is down 33.5% since the beginning of the year, and at $19.45 per share, it is trading 46.8% below its 52-week high of $36.57 from March 2025. Investors who bought $1,000 worth of Baxter’s shares 5 years ago would now be looking at an investment worth $250.78.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
